CDKN2A and melanoma: To validate the ICD triggered by treatment, we tested our drug combination on two mouse melanoma lines (YUMMUV1.7 and YUMMUV3.3) derived from YUMM1.7 (Braf V600E:Cdkn2a−/−:Pten−/−) and YUMM 3.3 (Braf V600E:Cdkn2a−/−) [21] and subjected to ultraviolet radiation in vitro utilising a modified protocol described [27].